GCM
HRTX icon

Graham Capital Management’s Heron Therapeutics HRTX Stock Holding History

Graham Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-22,304
Closed -$78.1K – 1196
2024
Q2 		$78.1K Buy
+22,304
New +$68.5K ﹤0.01% 962
2023
Q4 		– Sell
-146,872
Closed -$151K – 1133
2023
Q3 		$151K Sell
146,872
-22,276
-13% -$31.7K ﹤0.01% 901
2023
Q2 		$196K Buy
169,148
+144,142
+576% +$257K 0.01% 826
2023
Q1 		$37.8K Buy
+25,006
New +$62.6K ﹤0.01% 1011
2022
Q4 		– Sell
-890,650
Closed -$3.76M – 1159
2022
Q3 		$3.76M Buy
+890,650
New +$3.49M 0.15% 82

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Graham Capital Management's HRTX Position: Q3 2024 in Review

Graham Capital Management sold out of Heron Therapeutics (HRTX) in Q3 2024, closing a stake of 22,304 shares — an estimated $78.1K sold.

Graham Capital Management first reported a position in HRTX in Q3 2022 and held it in 5 quarters. The position peaked at $3.76M in Q3 2022. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

  • Graham Capital Management reported no remaining Heron Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Graham Capital Management sold 22,304 Heron Therapeutics shares in Q3 2024, an estimated $78.1K.
  • Graham Capital Management first reported a position in Heron Therapeutics in Q3 2022 and held it in 5 quarters.
  • Graham Capital Management's Heron Therapeutics position peaked at $3.76M in Q3 2022.
  • 173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on Graham Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.